Shroom Boom – Magic Mushrooms Could Be the Next Investment Trend

According to the National Institute of Health, more than forty million Americans, just a small portion of the world’s population, are diagnosed with anxiety and depression, making it one of the most prevalent mental illnesses worldwide. Currently, the methods used for treatment aren’t adding up to curb this defect. But the upcoming unique compounds give a ray of hope to the researchers. Some companies, such as the Champignon Brand, are developing a therapy approach that proves to be more effective than the existing adopted pharmaceutical approaches used to treat mental illness, depression, and anxiety. Following this demand, a completely new market opportunity for shrooms to make psilocybin substances has become a front-page discussion. This article explains the need to adopt this product.

Magic mushrooms are naturally broken through, produced “special compounds.” Traditionally pre-existing anti depressions don’t count entirely predictable in the treatment of related mental complications. As a result, several problems arise from patients having symptoms of chronic depression. Selective serotonin reuptake inhibitors (SSRIs), the popular prescribed antidepressants contain Zoloft derived from Pfizer (PFE). This compound is among the most known antidepressants. This medication approach functions by limiting serotonin back movement into the nerve endings; fundamentally, it makes more chemical availability body utilization. It is essential since low serotonin levels are linked to triggering anxiety, depression, and causes some behaviours resulting from obsessive-compulsive. Pfizer’s Zoloft is uniquely classified among many other SSRIs because it has been scientifically proven to pose minimum adverse side complications. Thus, ranking its functionality to be one of the first medicinal trials for many participants diagnosed with depression.

Taking into consideration Teva Pharmaceutical Industries Ltd. (TEVA), an aggressively expanding and acquisitions reputed firm, has played a significant part in helping patients having mental complications. This organization focuses specifically on the non-brand-name; thus, treatment for depression has relatively been cheap and affordable. This medication includes venlafaxine, the widely popular Lexapro, and escitalopram. Nowadays, the medical field responsible for mental complications is drifting to the newly discovered product that is expected to alleviate symptoms in a much more effective approach than the traditional adopted medication techniques.  

Ketamine, a psychedelic product, is considered an effective anesthetic tranquilizer and drug. The product has medically shown significant benefits as an approach adopted in treating anxiety and depression when applied in tiny micro dosage. FDA has allowed it on a limited basis after many years of resistance as the first-ever legal ketamine derived drug in conjunction with nasal spray. Spravato, a pharmaceutical giant developed by Johnson & Johnson (JNJ), has been highly recognized in the medical field since it has an overwhelming advantage over its patients. The drug responds positively to depression symptoms for a period of up to four weeks. Even though patients are usually unable to apply the dosage in the absence of direct supervision from their healthcare providers, the process has proven to be sustainable and safe in the long run. Notwithstanding, ketamine has captured the wave of depression treatment. The other two compounds, namely psilocybin and MDMA has portrayed identical effects.

Besides, psilocybin aims to contribute eminently to post-traumatic stress disorder (PTSD), the most common condition among military veterans. Consequently, according to the latest statistics, the development of PTSD is furthermore comprehensive than ideally known. Currently, the adopted treatment entails therapy, medications, and counselling. Generally, when compounds in the ketamine are applied and administered in micro dosage repeatedly, psilocybin and MDMA can significantly alleviate symptoms resulting from depression. To some extent, Champignon has a chance to be inside track within the psilocybin.

Shroom Boom could be the next investment trend due to the market size of 450 million people. Mental health has become a worldwide challenge; on the other hand, this challenge is an opportunity for potential companies to have an innovative approach. Moreover, investors are aiming to buy into small scale firms. According to the WHO, most people are likely to be affected by mental disorders. Currently, approximately 450 million people are diagnosed with mental illness and seek treatment, most of which are ineffective and expensive. The Psilocybin mushroom market has upgraded progressively and would probably hit $34.3 billion by 2024 as per the forecast.

In conclusion, the rise for shrooms will follow a clear up tread to adequately satisfy the exponentially rising medical demand for psilocybin derived products. This, besides, would be due to the 450 million global markets. In recommendation, psilocybin mushroom should be considered to be legalized.

Leave a Reply